Current approaches of nanomedicines in the market and various stage of clinical translation

Shan, Xiaoting; Gong, Xianzu; Li, Jie; Wen, Jingyuan; Li, Yaping; Zhang, Zhiwen

doi:10.1016/j.apsb.2022.02.025

Cited by 144 publications

(138 citation statements)

References 198 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since 1995, when the first nanomedicine, Doxil, was commercialized, approximately 60 nanomedicines and 100 nanomedicine-related products have been registered around the world (Abdellatif and Alsowinea, 2021;Shan et al, 2022). The most recent approvals were given to mRNA-Covid-19 vaccines that use lipid nanoparticles to deliver mRNA to monocytes and dendritic cell subsets for immunization against SARS-CoV-2 (Shan et al, 2022;Trougakos et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Leishmaniasis and Chagas disease: Is there hope in nanotechnology to fight neglected tropical diseases?

Scariot

Staneviciute

Zhu

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Nanotechnology is revolutionizing many sectors of science, from food preservation to healthcare to energy applications. Since 1995, when the first nanomedicines started being commercialized, drug developers have relied on nanotechnology to improve the pharmacokinetic properties of bioactive molecules. The development of advanced nanomaterials has greatly enhanced drug discovery through improved pharmacotherapeutic effects and reduction of toxicity and side effects. Therefore, highly toxic treatments such as cancer chemotherapy, have benefited from nanotechnology. Considering the toxicity of the few therapeutic options to treat neglected tropical diseases, such as leishmaniasis and Chagas disease, nanotechnology has also been explored as a potential innovation to treat these diseases. However, despite the significant research progress over the years, the benefits of nanotechnology for both diseases are still limited to preliminary animal studies, raising the question about the clinical utility of nanomedicines in this field. From this perspective, this review aims to discuss recent nanotechnological developments, the advantages of nanoformulations over current leishmanicidal and trypanocidal drugs, limitations of nano-based drugs, and research gaps that still must be filled to make these novel drug delivery systems a reality for leishmaniasis and Chagas disease treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Leishmaniasis and Chagas disease: Is there hope in nanotechnology to fight neglected tropical diseases?

Scariot

Staneviciute

Zhu

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Nanoparticles based on polymer-drug/protein conjugates, polymers, micelles, and dendrimers are currently undergoing preclinical trials or have been used clinically, and they can be used as potential therapeutic modalities in tumour immunotherapy. 311 Specifically, in Table 2 we list the clinical trials of nanogels composed of CHP for immunotherapy. How to achieve the precise release of drugs at the site of the tumour lesion and how to improve the response rate of tumour immunotherapy are still challenging; thus, bioengineered nanogels with precise drug release may play a vital role in inducing immunogenicity at the tumour and improving drug availability.…”

Section: Challenges and Future Perspectives For Clinical Transformationmentioning

confidence: 99%

Bioengineered nanogels for cancer immunotherapy

Liu

et al. 2022

Chem. Soc. Rev.

View full text Add to dashboard Cite

show abstract

“…where v c is the volume of the hydrocarbon chain, a 0 is the area of the headgroup, and l c is the maximum length of the hydrocarbon chain in the fluid environment. The volume can be determined according to Equation (2). Depending on the number of carbons, n c , the volume can be calculated with:…”

Section: Packing Parameter and Spontaneous Curvaturementioning

confidence: 99%

“…As an example, nanotechnology allowed the development of carriers enhancing drug delivery efficiency, which led to a higher treatment effectiveness. Different authors stated that the combination of nanocarriers with active pharmaceutical ingredients [1,2], resulted in an efficient and safe cancer immunotherapy [3,4]. This new approach significantly reduced the negative effects by enabling the selective accumulation of the toxic drug in the desired area, reducing the dose received by healthy tissues [5].…”

Section: Introductionmentioning

confidence: 99%

A Versatile Nanocarrier—Cubosomes, Characterization, and Applications

et al. 2022

View full text Add to dashboard Cite

The impact of nanotechnology on the exponential growth of several research areas, particularly nanomedicine, is undeniable. The ability to deliver active molecules to the desired site could significantly improve the efficiency of medical treatments. One of the nanocarriers developed which has drawn researchers’ attention are cubosomes, which are nanosized dispersions of lipid bicontinuous cubic phases in water, consisting of a lipidic interior and aqueous domains folded in a cubic lattice. They stand out due to their ability to incorporate hydrophobic, hydrophilic, and amphiphilic compounds, their tortuous internal configuration that provides a sustained release, and the capacity to protect and safely deliver molecules. Several approaches can be taken to prepare this structure, as well as different lipids like monoolein or phytantriol. This review paper describes the different methods to prepare nanocarriers. As it is known, the physicochemical properties of nanocarriers are very important, as they influence their pharmacokinetics and their ability to incorporate and deliver active molecules. Therefore, an extensive characterization is essential to obtain the desired effect. As a result, we have extensively described the most common techniques to characterize cubosomes, particularly nanocarriers. The exceptional properties of the cubosomes make them suitable to be used in several applications in the biomedical field, from cancer therapeutics to imaging, which will be described. Taking in consideration the outstanding properties of cubosomes, their application in several research fields is envisaged.

show abstract

Current approaches of nanomedicines in the market and various stage of clinical translation

Cited by 144 publications

References 198 publications

Leishmaniasis and Chagas disease: Is there hope in nanotechnology to fight neglected tropical diseases?

Leishmaniasis and Chagas disease: Is there hope in nanotechnology to fight neglected tropical diseases?

Bioengineered nanogels for cancer immunotherapy

A Versatile Nanocarrier—Cubosomes, Characterization, and Applications

Contact Info

Product

Resources

About